|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 31/436 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61P 35/04 | (2006.01) |
| (11) | Number of the document | 3351246 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18155644.0 |
| Date of filing the European patent application | 2002-02-18 | |
| (97) | Date of publication of the European application | 2018-07-25 |
| (45) | Date of publication and mention of the grant of the patent | 2019-05-22 |
| (46) | Date of publication of the claims translation | 2019-07-10 |
| (30) | Number | Date | Country code |
| 0104072 | 2001-02-19 | GB | |
| 0124957 | 2001-10-17 | GB |
| (72) |
Lane, Heidi, CH
O`Reilly, Terence, CH
Wood, Jeanette Marjorie, CH
|
| (73) |
Novartis Pharma AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis International Pharmaceutical AG, Lichtstrasse 35, 4056 Basel, CH |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui |
| RAPAMYCIN DERIVATIVE FOR THE TREATMENT OF A SOLID TUMOR ASSOCIATED WITH DEREGULATED ANGIOGENESIS |
| Payment date | Validity (years) | Amount | |
| 2021-01-28 | 347.00 EUR |